Brief: Pharming Group NV Receives Positive CHMP Opinion for Joenja

Pharming NV

27/03/2026 06:15

March 27 (Reuters) - Pharming Group NV PHAR.AS:

CHMP ISSUES POSITIVE OPINION FOR JOENJA (LENIOLISIB) MARKETING AUTHORIZATION

EUROPEAN COMMISSION FINAL DECISION ON JOENJA EXPECTED IN Q2 2026

JOENJA RECOMMENDED FOR APDS TREATMENT IN PATIENTS AGED 12 YEARS AND OLDER

JOENJA MARKETING AUTHORIZATION WOULD COVER EU, NORWAY, ICELAND, LIECHTENSTEIN

JOENJA WOULD BE FIRST APPROVED APDS TREATMENT IN EUROPEAN UNION IF APPROVED

Source text: ID:nGNE2ZS4GZ

Further company coverage: PHAR.AS

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))